Tickerover
Healthcare

PEN Stock Analysis

Penumbra, Inc. · current price $321.67 (+0.07% today)

Mixed signals — neither side has the edge here. The thesis lacks a clear edge from current data.
★★★
Average
📊

The six-pillar scorecard

Momentum
56
Drifting higher
price trend
Growth
25
Barely growing
sales & profit growth
Quality
95
High quality
profitability & balance sheet
Valuation
25
Expensive
is the price fair?
Sentiment
32
Out of favour
analyst & crowd mood
Risk
75
Low risk
volatility & drawdown

Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.

📉

The picture

What drove the scoreThe seven components contributing most, each read out of 100.
1-month momentum1-month momentum: 5050RSI zoneRSI zone: 7070Relative strengthRelative strength: 6565Trend strengthTrend strength: 6565GrowthGrowth: 3838Near 52w highNear 52w high: 6060Earnings qualityEarnings quality: 6060
Margin profileWhat survives each step down the income statement.
GrossGross: 67.8%67.8%OperatingOperating: 10.5%10.5%NetNet: 10.7%10.7%Free cash flowFree cash flow: 14.3%14.3%
EPS surpriseReported EPS against estimate, last four quarters.
2026-06: -14.4% vs estimate-14%2026-062026-03: -4.6% vs estimate-5%2026-032025-12: +6.1% vs estimate+6%2025-122025-09: +5.3% vs estimate+5%2025-09
👁

Hype Check

Reading PEN’s price and volume history…

The audit — what has to hold for this thesis

Checking the areas that decide this thesis…

AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.

🛡

Dilution Check

Reading PEN’s filings…

📣

Latest earnings

LAST EARNINGS Penumbra, Inc. (PEN)

Latest earnings

EPS
$0.97 vs $0.92 est · +5.3% vs estimate BEAT
Revenue
$390.0M · +10.0% YoY
Stock reaction (1M)
+0.6%
Beat streak
2 of last 4 quarters
💰

Valuation

P/E
78.7×
Forward P/E
52.5×
PEG
4.35
Price / Sales
8.4×
Price / Book
8.3×
EV / EBITDA
59.8×
Analyst target
$361.83
Target range
$323.00 – $374.00
Implied upside
+12.5%
🩺

Financial health

Gross margin
67.8%
Operating margin
10.5%
Net margin
10.7%
FCF margin
14.3%
Return on equity
11.4%
Debt / equity
0.14
Revenue growth YoY
+14.9%
EPS growth YoY
-23.5%
📈

Technicals

$221.2652-week range$362.41
RSI (14)
45
50-day MA
$320.61
200-day MA
$323.45
ATR (14)
2.11
Beta
0.70
1-month return
+0.6%
🗓️

Earnings

QuarterEPSEst.SurpriseResult
2025-09-30$0.97$0.92+5.3%Beat
2025-12-31$1.18$1.11+6.1%Beat
2026-03-31$1.01$1.06-4.6%Miss
2026-06-30$1.01$1.18-14.4%Miss
Beat 2 of the last 4 quarters.
🏛️

Ownership & risk

Short % of float
0.05%
Beta
0.70
📰

Latest news on PEN

🔗

Similar stocks in Healthcare

Frequently asked

What is PEN's Quant Score?

Penumbra, Inc. (PEN) currently has a TickerMover Quant Score of 56/100, rated ★★★ Average. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.

Is Penumbra, Inc. (PEN) a buy?

TickerMover does not give buy or sell recommendations. PEN scores 56/100 (★★★ Average) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.

How often is PEN's score updated?

PEN's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.

Get the full live dashboard

Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.

Open the dashboard for PEN →